Table 1.
Baseline parameters of the study cohort by degrees of fibrosis.
| F0-F2 (Metavir) N=118 Absolute (relative) counts or mean ± SEM |
F3 (Metavir) N=80 Absolute (relative) counts or mean ± SEM |
F4 (Metavir) N=170 Absolute (relative) counts or mean ± SEM |
P | |
|---|---|---|---|---|
| Male sex | 58 (49.2) | 34 (42.5) | 75 (42.4) | 0.477 |
|
| ||||
| Age (years) | 53.64±1.339 | 60.56±1.297 | 61.08±0.743 | <0.0001 |
|
| ||||
| Duration of HCV infection (years) | 9.37±0.72 | 10.82±0.75 | 11.06±0.59 | 0.158 |
|
| ||||
| BMI | 26.17±0.50 | 27.96±0.51 | 26.94±0.35 | 0.037 |
|
| ||||
| genotype 1b | 93 (78.8) | 73 (91.3) | 149 (87.6) | 0.002 |
| genotype 1a | 14 (11.9) | 5 (6.3) | 4 (2.4) | |
| genotype 1 (unspecified) | 4 (3.4) | 2 (2.5) | 13 (7.6) | |
| genotype 3 | 7 (5.9) | 0 | 4 (2.4) | |
| genotype other | 0 | 0 | 0 | |
|
| ||||
| Naïve | 53 (44.9) | 14 (17.5) | 43 (25.3) | <0.0001 |
| Experienced | 65 (55.1) | 66 (82.5) | 127 (74.7) | |
|
| ||||
| Relapse | 19 (32.2) | 35 (56.5) | 38 (30.9) | 0.009 |
| Partial response | 9 (15.3) | 7 (11.3) | 14 (11.4) | |
| Breakthrough | 5 (8.5) | 8 (12.9) | 14 (11.4) | |
| Nonresponse | 26 (44.1) | 12 (19.4) | 57 (56.3) | |
|
| ||||
| HBsAg positive | 3 (2.5) | 0 | 1 (0.6) | 0.166 |
|
| ||||
| HIV positive | 0 | 0 | 0 | N/A |
|
| ||||
| Treatment for hypertension | 33 (30.3) | 35 (46.7) | 72 (47.1) | 0.015 |
|
| ||||
| Treatment for dyslipidemia | 7 (6.4) | 11 (14.7) | 41 (26.8) | <0.0001 |
|
| ||||
| Treatment for T2DM | 12 (10.2) | 12 (15.0) | 34 (20.0) | 0.078 |
|
| ||||
| Diet only | 2 (20) | 5 (55.6) | 8 (30.8) | 0.024 |
| OAD only | 5 (50) | 4 (44.4) | 4 (15.4) | |
| Insulin | 3 (30) | 0 | 14 (53.8) | |
|
| ||||
| Extrahepatic manifestations | 23 (19.5) | 10 (12.5) | 15 (8.8) | 0.03 |
|
| ||||
| HCC | 1 (0.8) | 2 (2.5) | 5 (2.9) | 0.475 |